A dose response study of hepatitis A vaccine in healthy adults who are ≤30 years old and weigh ≤77 kg

Journal of Infectious Diseases

Volumn 178, Issue 4, 1998, Pages 1181-1184

  Bertino Jr , Joseph S ^a   Thoelen, Stefan ^b   VanDamme, Pierre ^b   Bryan, Joe P ^b   Becherer, Paul R ^b   Frey, Sharon ^b   Hayden, Fredrick G ^b   Marcus, Leonard C ^b   Parenti, David M ^b   Sperling, Malcolm ^b   Chan, Ivan S F ^b   Brown, Leora ^b   Nalin, David ^b  

^a BASSETT HEALTHCARE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADULT; AGE; ANTIBODY BLOOD LEVEL; ARTICLE; BODY WEIGHT; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION;

EID: 17344374392     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515680     Document Type: Article

References (13)

1. Anonymous. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Moral Wkly Rep 1996;45(RR-15):1-30.
2. Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects. Baltimore: Williams & Wilkins, 1991:14-20.
3. Dalton CB, Haddex A, Hoffman RE, Mosi EE. The cost of a foodborne outbreak of hepatitis A in Denver, Colorado. Arch Intern Med 1996; 156:1013-6.
4. Iwarson S. Immunization against hepatitis A - active or passive? Infection 1996;24:2-4.
5. Innis BL, Snitbhanr, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328-34.
6. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1993; 327:453-7.
7. Nalin DR, Kuter BJ, Brown L, et al. Worldwide experience with the CR326F-derived inactivated hepatitis A vaccine in pediatric and adult populations: an overview. J Hepatol 1993;18(suppl 2):S51-5.
8. Miller WJ, Clark W, Hurni W, et al. Sensitive assays for hepatitis A antibodies. J Med Virol 1993;41:201-4.
9. SAS. SAS user's guide: Cary, NC: SAS Institute, 1985.
10. 2 tests. Biometrics 1954;10:417-51.
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
12. Shouval D, Ashur Y, Adler R, et al. Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections and comparison to administration of immune globulin. J Hepatol 1993;18(suppl 2):S32-7.
13. VanDamme P, Mathei C, Thoelen S, et al. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 1994;44:435-41.